Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV Specific CTLs for Refractory CMV Infections
NCT03266640Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of viral specific cytotoxic t-lymphocytes in Refractory cytomegalovirus infection (R-CMV), sponsored by New York Medical College. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks and Incidence of Response to Treatment at 12 weeks. Started Nov 2018; status: recruiting.
02
Drugs
viral specific cytotoxic t-lymphocytes
03
Conditions
Refractory cytomegalovirus infection (R-CMV)
Beyond the preview
Go deeper on NCT03266640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266640.